#1 Clinical Trials Search in Europe

Repotrectinib

Repotrectinib is an innovative drug being studied in clinical trials for various advanced cancers, particularly non-small cell lung cancer (NSCLC) with specific genetic alterations. These trials aim to evaluate the safety, efficacy, and potential benefits of repotrectinib in treating patients with limited treatment options. The drug shows promise in targeting specific genetic mutations and potentially overcoming resistance to existing therapies.

Table of Contents

What is Repotrectinib?

Repotrectinib is a new and promising cancer medication currently being studied in clinical trials. It’s also known by other names such as BMS-986472 and TPX-0005[1][2]. This drug belongs to a class of medications called tyrosine kinase inhibitors (TKIs), which are designed to target specific proteins in cancer cells[3].

What Conditions Does Repotrectinib Treat?

Repotrectinib is being studied for the treatment of several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. Repotrectinib is specifically being studied in patients with NSCLC that has certain genetic changes, such as ROS1 gene rearrangements[4].
  • Solid tumors: These are cancers that form solid masses in the body, such as breast cancer or colon cancer[2].
  • Brain metastases: These are cancer cells that have spread from their original site to the brain[4].
  • Primary CNS tumors: These are cancers that start in the brain or spinal cord[2].
  • Lymphoma: This is a type of cancer that affects the lymphatic system[2].

How Does Repotrectinib Work?

Repotrectinib works by targeting specific proteins in cancer cells. It’s designed to inhibit several proteins, including:

  • ROS1: A protein that, when altered, can contribute to cancer growth[4].
  • ALK: Anaplastic Lymphoma Kinase, another protein involved in some cancers[2].
  • NTRK1-3: Neurotrophic Tyrosine Receptor Kinase, a family of proteins that can drive cancer growth when altered[2].

By blocking these proteins, repotrectinib aims to stop or slow down the growth of cancer cells[3].

Current Clinical Trials

Repotrectinib is currently being studied in several clinical trials:

  • REPOSE Study: This study is looking at how well repotrectinib works in patients with NSCLC that has spread to the brain[4].
  • TRIDENT-3: This is a larger study comparing repotrectinib to another drug called crizotinib in patients with advanced NSCLC[1].
  • Pediatric and Young Adult Study: This study is testing repotrectinib in younger patients with various types of cancer[2].
  • REPLOT Trial: This study is looking at repotrectinib in combination with another drug called fulvestrant for a specific type of breast cancer[5].

How is Repotrectinib Administered?

Repotrectinib is taken orally, usually in the form of capsules. The exact dosage can vary depending on the specific study and the patient’s condition. In some studies, patients start with a lower dose and then increase to a higher dose over time[4]. The capsules are typically swallowed whole with water or another liquid, and can be taken with or without food[4].

Potential Side Effects

As with any medication, repotrectinib may cause side effects. The full range of potential side effects is still being studied in clinical trials. Common side effects of similar drugs may include nausea, fatigue, and diarrhea. However, it’s important to note that not everyone experiences side effects, and they can vary from person to person. In the clinical trials, researchers are carefully monitoring patients for any adverse events[1].

Future Prospects

Repotrectinib shows promise in treating various types of cancer, particularly those with specific genetic alterations. If the ongoing clinical trials show positive results, it could become an important new treatment option for patients. Researchers are particularly interested in its potential to treat cancers that have spread to the brain, as this is an area where new treatments are greatly needed[4].

It’s important to remember that repotrectinib is still an experimental drug. While early results are promising, more research is needed to fully understand its effectiveness and safety. Patients interested in repotrectinib should discuss with their healthcare provider whether participating in a clinical trial might be appropriate for their situation.

Aspect Details
Drug Name Repotrectinib (also known as BMS-986472, TPX-0005)
Primary Target Cancers Advanced or metastatic non-small cell lung cancer (NSCLC) with ROS1 gene rearrangements
Other Target Cancers Solid tumors and lymphomas with ALK, NTRK1-3 alterations
Administration Oral capsules, typically once or twice daily
Key Clinical Trials REPOSE, TRIDENT-3, pediatric/young adult studies
Main Objectives Assess safety, efficacy, pharmacokinetics, and anti-tumor activity
Key Outcome Measures Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), intracranial response
Special Populations Studies include patients with brain metastases, pediatric/young adult patients, and those with hepatic impairment
Combination Studies Being tested in combination with osimertinib and fulvestrant in specific cancer types

FAQ

  • What is repotrectinib? Repotrectinib is a new-generation tyrosine kinase inhibitor (TKI) designed to target specific genetic alterations in cancer cells, particularly those involving ROS1, ALK, and NTRK genes. It is being studied as a potential treatment for various advanced cancers, especially non-small cell lung cancer (NSCLC).
  • What types of cancer is repotrectinib being studied for? Repotrectinib is primarily being studied for advanced or metastatic non-small cell lung cancer (NSCLC) with ROS1 gene rearrangements. It is also being investigated for other solid tumors and certain types of lymphoma with specific genetic alterations, including ALK and NTRK gene changes.
  • How is repotrectinib administered? Repotrectinib is typically administered orally in the form of capsules. The dosage and frequency may vary depending on the specific clinical trial and patient characteristics. In some studies, it is given once or twice daily, with or without food.
  • What are the potential benefits of repotrectinib? Repotrectinib has shown potential in treating cancers that have become resistant to other TKIs. It may be effective in shrinking tumors, slowing disease progression, and improving survival in patients with specific genetic alterations. Some studies are also exploring its efficacy in treating brain metastases.
  • Are there any side effects associated with repotrectinib? As with any medication, repotrectinib may cause side effects. The specific side effects and their severity are being closely monitored in clinical trials. Common side effects of TKIs can include fatigue, nausea, and changes in liver function. The trials are designed to assess the safety and tolerability of repotrectinib in various patient populations.

Ongoing Clinical Trials on Repotrectinib

  • Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium Denmark France Germany Hungary Italy +3

  • Study of Repotrectinib for Frail or Elderly Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Rearrangement

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Spain

  • Study on Repotrectinib for Children and Young Adults with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Alterations

    Recruiting

    1 1 1
    Investigated drugs:
    Denmark France Italy Spain

  • Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Greece Hungary Italy +4

Glossary

  • Tyrosine Kinase Inhibitor (TKI): A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • ROS1 gene rearrangement: A genetic alteration where the ROS1 gene fuses with another gene, leading to abnormal cell growth and cancer development, particularly in some types of lung cancer.
  • Non-small cell lung cancer (NSCLC): The most common type of lung cancer, accounting for about 80-85% of all lung cancers. It includes subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Brain metastases: Cancer that has spread from its original site to the brain.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standardized method to measure tumor response in cancer clinical trials.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Maximum tolerated dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • Blinded Independent Central Review (BICR): A method used in clinical trials where independent experts review patient data without knowing which treatment the patient received, to ensure unbiased assessment of results.

References